KANTREX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kantrex, and when can generic versions of Kantrex launch?
Kantrex is a drug marketed by Apothecon and is included in six NDAs.
The generic ingredient in KANTREX is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KANTREX?
- What are the global sales for KANTREX?
- What is Average Wholesale Price for KANTREX?
Summary for KANTREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 141 |
| Clinical Trials: | 2 |
| DailyMed Link: | KANTREX at DailyMed |
Recent Clinical Trials for KANTREX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| McMaster University | N/A |
| IUATLD, Inc | Phase 3 |
| Liverpool School of Tropical Medicine | Phase 3 |
US Patents and Regulatory Information for KANTREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | KANTREX | kanamycin sulfate | CAPSULE;ORAL | 060516-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | KANTREX | kanamycin sulfate | INJECTABLE;INJECTION | 061655-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | KANTREX | kanamycin sulfate | INJECTABLE;INJECTION | 061655-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
